Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Häupl B, Mohr S, Rao AV, Walker AR, Blachly JS, Piccioni F, Armstrong SA, Byrd JC, Oellerich T, Stegmaier K. Cremer A, et al. Among authors: pikman y. Cancer Discov. 2020 Feb;10(2):214-231. doi: 10.1158/2159-8290.CD-19-0209. Epub 2019 Nov 26. Cancer Discov. 2020. PMID: 31771968 Free PMC article.
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K. Puissant A, et al. Among authors: pikman y. Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022. Cancer Cell. 2014. PMID: 24525236 Free PMC article.
Targeting MTHFD2 in acute myeloid leukemia.
Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K. Pikman Y, et al. J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20. J Exp Med. 2016. PMID: 27325891 Free PMC article.
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. Fenouille N, et al. Among authors: pikman y. Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13. Nat Med. 2017. PMID: 28191887 Free PMC article.
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB. Wagner FF, et al. Among authors: pikman y. Sci Transl Med. 2018 Mar 7;10(431):eaam8460. doi: 10.1126/scitranslmed.aam8460. Sci Transl Med. 2018. PMID: 29515000 Free PMC article.
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB. Place AE, et al. Among authors: pikman y. Pediatr Blood Cancer. 2018 Jul;65(7):e27062. doi: 10.1002/pbc.27062. Epub 2018 Mar 30. Pediatr Blood Cancer. 2018. PMID: 29603593 Clinical Trial.
Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.
Pikman Y, Conway AS, Robichaud AL, Kitara S, Church AJ, Kennedy AL, Silverman LB, Billett AL, Weinstock DM, Harris MH, Stegmaier K. Pikman Y, et al. Blood Adv. 2020 Apr 14;4(7):1265-1269. doi: 10.1182/bloodadvances.2019001256. Blood Adv. 2020. PMID: 32232478 Free PMC article.
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debré I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, Roti G, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant A. Su A, et al. Among authors: pikman y. Cancer Discov. 2020 Dec;10(12):1894-1911. doi: 10.1158/2159-8290.CD-19-0970. Epub 2020 Aug 21. Cancer Discov. 2020. PMID: 32826232 Free PMC article.
48 results